Milrinone: basic and clinical pharmacology and acute and chronic management.

Article Details

Citation
Copy to clipboard

Shipley JB, Tolman D, Hastillo A, Hess ML

Milrinone: basic and clinical pharmacology and acute and chronic management.

Am J Med Sci. 1996 Jun;311(6):286-91. doi: 10.1097/00000441-199606000-00011.

PubMed ID
8659556 [ View in PubMed
]
Abstract

Milrinone (Inocor-Sanofi-Winthrop) represents a second generation phosphodiesterase inhibitor currently approved for intravenous administration in the treatment of decompensated congestive heart failure. By inhibiting Type III phosphodiesterase, milrinone increases intracellular cyclic adenosine monophosphate. This results in a positive inotropic effect on the heart and vasodilatation in the periphery. The hemodynamic consequences of this action produce left ventricular afterload reduction, with an increase in cardiac output and a reduction in total peripheral resistance. Unlike the sympathomimetic amines, milrinone produces no tolerance and possesses the distinct advantage of directly decreasing pulmonary vascular resistance. Short-term intermittent infusion by peripheral administration, continuous infusion, long-term therapy, and intermittent outpatient therapy was demonstrated to be safe, efficacious, and cost effective. It is hypothesized that intravenous milrinone, by producing biventricular afterload reduction, offers an efficacious, cost-effective tool for the treatment of decompensated heart failure.

DrugBank Data that Cites this Article

Drugs